Pluri Inc. PLUR
Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026
Pluri Inc. (PLUR) is a healthcare company listed in the US with a market value of about $15M. In the twelve months to September 30, 2026 it had revenue of $1M and net income of -$28M, a net margin of -1943.9%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -55%.
About Pluri
Pluri is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $379000 in 2015 to $1M in 2026, growth of about 9.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 113% over three years (dilution for shareholders). It spends 1485% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $1M | $1M | $326000 | $287000 | $234000 | — | $23000 | $54000 | $50000 | — |
| Net income | -$28M | -$24M | -$23M | -$21M | -$28M | -$41M | -$50M | -$29M | -$35M | -$26M | -$28M |
| Free cash flow | -$19M | -$20M | -$20M | -$18M | -$23M | -$37M | -$31M | -$27M | -$30M | -$22M | -$22M |
| EPS (diluted) | $-2.33 | $-2.44 | $-3.56 | $-3.99 | $-6.24 | $-10.24 | $-14.16 | $-12.80 | $-23.20 | $-20.00 | $-25.60 |
| Net margin | -1943.9% | -2344.6% | -1690.3% | -6407.4% | -9867.9% | -17624.8% | — | -126700.0% | -65383.3% | -52252.0% | — |
| ROIC | — | — | — | -58.9% | -49.8% | -55.8% | -48.9% | -39.5% | -128.6% | -93.5% | -73.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Pluri pay a dividend?
Not currently.
Is Pluri a good stock to buy?
We do not give buy or sell advice. Pluri scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.